Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Zinc-Alpha-2-Glycoprotein Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:ZA2G, ZAG, AZGP1, Zn-alpha-2-glycoprotein, Zn-alpha-2-GP, ZNGP1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD191093100R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

10 µl/well

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

3–100 ng/ml

Limit of Detection

Analytical Limit of Detection is calculated from the real Zinc-Alpha-2-Glycoprotein values in wells and is 0.673 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 3.9%

Inter-assay (Run-to-Run)

n = 4; CV = 6.6%

Spiking Recovery

96,20%

Dilutation Linearity

103,30%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • chicken Not tested
  • human Yes
  • monkey Yes (recommended dilution 1:400)
  • rat Non-detectable
  • sheep Non-detectable
Summary

Features

  • It is intended for research use only
  • The total assay time is less than 3 hours
  • The kit measures zinc-alpha-2-glycoprotein in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based. No animal sera are used
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Energy metabolism and body weight regulation, Oncology

Summary

Zinc-alpha-2-glycoprotein (ZAG, ZA2G, Azgp1, ZNGP1, Lipid-Mobilizing Factor, LMF) is a soluble 41 kDa glycoprotein belonging to the immunoglobuline protein family and consisting of a single polypeptide chain. Human ZAG shares 59% sequence identity with the murine homolog.

ZAG is closely related to antigens of the class1 major histocompatibility complex (MHC I) and shares 30-40 % sequence identity with the heavy chain of MHC I. Most MHC-I members heterodimerize with beta-2-microglobuline (b2m) and bind peptides derived from intracellular proteins to present them to cytotoxic T cells. In contrast, ZAG is a soluble protein rather than being anchored to plasma membranes that acts independently on b2m and binds the hydrophobic ligand which may relate to its function in lipid metabolism.

ZAG is widespread in body fluids and is also found in various human tissues such as adipose tissue, prostate, breast, skin, salivary gland, trachea, broncheus, lung, gastrointestinal tract, pancreas, liver and kidney. ZAG acts as a lipid mobilizing factor to induce lipolysis in adipocytes and plays an important role in lipid utilization and loss of adipose tissue, especially during cachexia, which occurs in patient suffering from cancer, AIDS and other chronic illnesses. The role of ZAG in cancer cachexia is also connected with its ability to directly influence expression of uncoupling proteins (UCPs) which are implicated in the regulation of energy balance. In human adipocytes, ZAG expression is regulated particularly through TNF-alpha and the PPAR gamma nuclear receptor. ZAG expression is also upregulated by glucocorticoides and attenuated by eicosapentaenoic acid (EPA) and beta-3-adrenoreceptor antagonists.

ZAG is overexpressed in certain human malignant tumors such as prostate, breast, lung or bladder cancer and can relate to tumor differentiation. Additionally, ZAG plays a role in obesity, diabetic kidney disorders, frontotemporal dementia and regulation of melanin production by melanocytes.

ZAG is proposed to have a therapeutic use in obesity and cachexia. It can be used as a marker for clinical analysis of diabetic nephropathy and as a marker for certain tumors..

References to Product

References

  • Aregger F, Pilop C, Uehlinger DE, Brunisholz R, Carrel TP, Frey FJ, Frey BM. Urinary proteomics before and after extracorporeal circulation in patients with and without acute kidney injury. J Thorac Cardiovasc Surg. 2010 Mar;139 (3):692-700
  • Brettschneider J, Mogel H, Lehmensiek V, Ahlert T, Sussmuth S, Ludolph AC, Tumani H. Proteome Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis (ALS). Neurochem Res. 2008 May 15;
  • Ceperuelo-Mallafre V, Escote X, Vilades C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, Leal M, Richart C, Vendrell J, Vidal F, Alba V, Aguilar A, Auguet T, Chacon MR, Lopez-Dupla M, Megia A, Miranda M, Olona M, Sauri A, Vargas M, Velasco I, Veloso S, Fontanet A, Gutierrez M, Mateo G, Munoz J, Sambeat MA. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. HIV Med. 2012 May;13 (5):297-303
  • Ceperuelo-Mallafre V, Naf S, Escote X, Caubet E, Gomez JM, Miranda M, Chacon MR, Gonzalez-Clemente JM, Gallart L, Gutierrez C, Vendrell J. Circulating and adipose tissue gene expression of zinc-alpha2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. J Clin Endocrinol Metab. 2009 Dec;94 (12):5062-9
  • Dichgans M, Petersen D. Angiographic complications in CADASIL. Lancet. 1997 Mar 15;349 (9054):776-7
  • Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009 Apr;150 (4):1688-96
  • Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS. Release of 12 Adipokines by Adipose Tissue, Nonfat Cells, and Fat Cells From Obese Women. Obesity (Silver Spring). 2009 Oct 15;
  • Felix K, Fakelman F, Hartmann D, Giese NA, Gaida MM, Schnolzer M, Flad T, Buchler MW, Werner J. Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci. 2011 Jan 31;88 (5-6):218-25
  • Gao D, Trayhurn P, Bing C. Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Mol Cell Endocrinol. 2010 Aug 30;325 (1-2):135-42
  • Garrido-Sanchez L, Garcia-Fuentes E, Fernandez-Garcia D, Escote X, Alcaide J, Perez-Martinez P, Vendrell J, Tinahones FJ. Zinc-alpha 2-glycoprotein gene expression in adipose tissue is related with insulin resistance and lipolytic genes in morbidly obese patients. PLoS One. 2012;7 (3):e33264
  • Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS, Shi YF. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond). 2009 Sep;33 (9):1023-30
  • Jernas M, Olsson B, Sjoholm K, Sjogren A, Rudemo M, Nellgard B, Carlsson LM, Sjostrom CD. Changes in adipose tissue gene expression and plasma levels of adipokines and acute-phase proteins in patients with critical illness. Metabolism. 2009 Jan;58 (1):102-8
  • Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Junior ML, Mafra D. Is zinc-alpha2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis?. Clin Chim Acta. 2012 Mar 22;413 (5-6):616-9
  • Lee YP, Chang CH, Liu HH, Chen CY, Chen CY, Hsu CC, Chang CI, Lin YT, Lee CS, Tsai JS. Plasma zinc alpha2-glycoprotein levels correlate positively with frailty severity in female elders. Medicine (Baltimore). 2016 Aug;95 (35):e4753
  • Mracek T, Ding Q, Tzanavari T, Kos K, Pinkney J, Wilding J, Trayhurn P, Bing C. The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clin Endocrinol (Oxf). 2010 Mar;72 (3):334-41
  • Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Ryden M, Arner P, Trayhurn P, Fearon KC, Bing C. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer. 2011 Feb 1;104 (3):441-7
  • Olofsson LE, Olsson B, Lystig T, Jacobson P, Jernas M, Sjoholm K, Gummesson A, Sjostrom L, Eriksson P, Hamsten A, Hale LP, Thelle DS, Carlsson B, Carlsson LM. Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids. Metabolism. 2010 Sep;59 (9):1316-8
  • Philipp A, Kralisch S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in chronic hemodialysis. Metabolism. 2011 May;60 (5):669-72
  • Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal. 2011 Mar 25;54 (4):817-25
  • Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers. 2009 Nov;14 (7):493-501
  • Selva DM, Lecube A, Hernandez C, Baena JA, Fort JM, Simo R. Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab. 2009 Nov;94 (11):4499-507
  • Simo R, Hernandez C, Saez-Lopez C, Soldevila B, Puig-Domingo M, Selva DM. Thyroid hormone upregulates zinc-alpha2-glycoprotein production in the liver but not in adipose tissue. PLoS One. 2014;9 (1):e85753
  • Somparn P, Hirankarn N, Leelahavanichkul A, Khovidhunkit W, Thongboonkerd V, Avihingsanon Y. Urinary proteomics revealed prostaglandin H(2)D-isomerase, not Zn-alpha2-glycoprotein, as a biomarker for active lupus nephritis. J Proteomics. 2012 Jun 18;75 (11):3240-7
  • Sorensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R. Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol. 2013;14:145
  • Stejskal D, Karpisek M, Reutova H, Stejskal P, Kotolova H, Kollar P. Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA. Clin Biochem . Nov 29 (2007)
  • Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A, Regolisti G, Fiaccadori E, Cabassi A. Serum adipokine zinc alpha2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metabolism. 2011 Jun 20;
  • Vanni H, Kazeros A, Wang R, Harvey BG, Ferris B, De BP, Carolan BJ, Hubner RH, O'Connor TP, Crystal RG. Cigarette smoking induces overexpression of a fat-depleting gene AZGP1 in the human. Chest. 2009 May;135 (5):1197-208
  • Wargent ET, O'Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ. Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol. 2013 Feb;216 (2):157-68
  • Yeung DC, Lam KS, Wang Y, Tso AW, Xu A. Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in chinese subjects. J Clin Endocrinol Metab. 2009 Jul;94 (7):2531-6
  • Zhu HJ, Wang XQ, Pan H, Gong FY, Zhang DX, Li NS, Wang LJ, Yang HB. Serum Levels of the Adipokine Zinc- alpha 2-glycoprotein Are Decreased in Patients with Hypertension. ISRN Endocrinol. 2014;2014:374090
  • Escoté X, Aranda GB, Mora M, Casals G, Enseñat J, Vidal O, Esteban Y, Halperin I, Hanzu FA. Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome. Endocrinol Diabetes Nutr. 2017 Jan;64(1):26-33. doi: 10.1016/j.endinu.2016.10.002
References to Summary

References to Zinc-Alpha-2-Glycoprotein

  • Araki T, Gejyo F, Takagaki K, Haupt H, Schwick HG, Burgi W, Marti T, Schaller J, Rickli E, Brossmer R, et al. Complete amino acid sequence of human plasma Zn-alpha 2-glycoprotein and its homology to histocompatibility antigens. Proc Natl Acad Sci U S A. 1988 Feb;85 (3):679-83
  • Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett. 2005 Jan 3;579 (1):41-7
  • Bennett MJ, Lebron JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature. 2000 Jan 6;403 (6765):46-53
  • Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A. 2004 Feb 24;101 (8):2500-5
  • Brysk MM, Lei G, Adler-Storthz K, Chen Z, Brysk H, Tyring SK, Arany I. Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Lett. 1999 Mar 22;137 (1):117-20
  • Brysk MM, Lei G, Selvanayagam P, Brysk H, Tyring SK, Arany I. Modulation by interferon-gamma of zinc-alpha 2-glycoprotein gene expression in human epithelial cell lines. Anticancer Res. 1997 Sep-Oct;17 (5A):3387-91
  • BURGI W, SCHMID K. Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem. 1961 Apr;236:1066-74
  • Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature. 1994 Nov 24;372 (6504):336-43
  • Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-Otin C. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer. 1993;29A (9):1256-60
  • Freije JP, Fueyo A, Uria JA, Velasco G, Sanchez LM, Lopez-Boado YS, Lopez-Otin C. Human Zn-alpha 2-glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes. Genomics. 1993 Dec;18 (3):575-87
  • Gohda T, Makita Y, Shike T, Tanimoto M, Funabiki K, Horikoshi S, Tomino Y. Identification of epistatic interaction involved in obesity using the KK/Ta mouse as a Type 2 diabetes model: is Zn-alpha2 glycoprotein-1 a candidate gene for obesity?. Diabetes. 2003 Aug;52 (8):2175-81
  • Hale LP. Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes. J Invest Dermatol. 2002 Aug;119 (2):464-70
  • Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res. 2001 Apr;7 (4):846-53
  • Hansson SF, Puchades M, Blennow K, Sjogren M, Davidsson P. Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci. 2004 Nov 18;2 (1):7
  • Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998 Jun 1;58 (11):2359-65
  • Im JS, Yu KO, Illarionov PA, LeClair KP, Storey JR, Kennedy MW, Besra GS, Porcelli SA. Direct measurement of antigen binding properties of CD1 proteins using fluorescent lipid probes. J Biol Chem. 2004 Jan 2;279 (1):299-310
  • Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind AS, Tatu U. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India. 2005 Jun;53:513-20
  • Kamoshida S, Watanabe K, Suzuki M, Mizutani Y, Sakamoto K, Sugimoto Y, Oka T, Fukushima M, Tsutsumi Y. Expression of cancer cachexia-related factors in human cancer xenografts: an immunohistochemical analysis. Biomed Res. 2006 Dec;27 (6):275-81
  • Lopez-Boa
Related Products Documents